Medical Care
Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Research Report 2025
- Jan 17, 26
- ID: 678622
- Pages: 85
- Figures: 89
- Views: 4
This report aims to provide a comprehensive presentation of the global market for Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service.
The Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza
uBriGene Biosciences International
Thermo Fisher
Creative Biolabs
REPROCELL
ATCC
Beijing CytoNiche Biotech
OmniaBio
Histocell
FUJIFILM Diosynth Biotechnologies
Taiwan Bio Therapeutics
Encell Co., Ltd.
Mycenax
Segment by Type
Cell Therapy
Cell-derived Products
Segment by Application
Large Pharmaceutical Company
Small and Medium-sized Pharmaceutical Company
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza
uBriGene Biosciences International
Thermo Fisher
Creative Biolabs
REPROCELL
ATCC
Beijing CytoNiche Biotech
OmniaBio
Histocell
FUJIFILM Diosynth Biotechnologies
Taiwan Bio Therapeutics
Encell Co., Ltd.
Mycenax
Segment by Type
Cell Therapy
Cell-derived Products
Segment by Application
Large Pharmaceutical Company
Small and Medium-sized Pharmaceutical Company
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cell Therapy
1.2.3 Cell-derived Products
1.3 Market by Application
1.3.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Large Pharmaceutical Company
1.3.3 Small and Medium-sized Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Perspective (2020-2031)
2.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Growth Trends by Region
2.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Region (2020-2025)
2.2.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Region (2026-2031)
2.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Dynamics
2.3.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industry Trends
2.3.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers
2.3.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges
2.3.4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Revenue
3.1.1 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Revenue (2020-2025)
3.1.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Players (2020-2025)
3.2 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue
3.4 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Concentration Ratio
3.4.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2024
3.5 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Head office and Area Served
3.6 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Product and Application
3.7 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Breakdown Data by Type
4.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Type (2020-2025)
4.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Type (2026-2031)
5 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Breakdown Data by Application
5.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Application (2020-2025)
5.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
6.2 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
6.4 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
7.2 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
7.4 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
8.2 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
9.2 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
9.4 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
10.2 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.1.4 Lonza Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.1.5 Lonza Recent Development
11.2 uBriGene Biosciences International
11.2.1 uBriGene Biosciences International Company Details
11.2.2 uBriGene Biosciences International Business Overview
11.2.3 uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.2.4 uBriGene Biosciences International Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.2.5 uBriGene Biosciences International Recent Development
11.3 Thermo Fisher
11.3.1 Thermo Fisher Company Details
11.3.2 Thermo Fisher Business Overview
11.3.3 Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.3.4 Thermo Fisher Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.3.5 Thermo Fisher Recent Development
11.4 Creative Biolabs
11.4.1 Creative Biolabs Company Details
11.4.2 Creative Biolabs Business Overview
11.4.3 Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.4.4 Creative Biolabs Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.4.5 Creative Biolabs Recent Development
11.5 REPROCELL
11.5.1 REPROCELL Company Details
11.5.2 REPROCELL Business Overview
11.5.3 REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.5.4 REPROCELL Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.5.5 REPROCELL Recent Development
11.6 ATCC
11.6.1 ATCC Company Details
11.6.2 ATCC Business Overview
11.6.3 ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.6.4 ATCC Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.6.5 ATCC Recent Development
11.7 Beijing CytoNiche Biotech
11.7.1 Beijing CytoNiche Biotech Company Details
11.7.2 Beijing CytoNiche Biotech Business Overview
11.7.3 Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.7.4 Beijing CytoNiche Biotech Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.7.5 Beijing CytoNiche Biotech Recent Development
11.8 OmniaBio
11.8.1 OmniaBio Company Details
11.8.2 OmniaBio Business Overview
11.8.3 OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.8.4 OmniaBio Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.8.5 OmniaBio Recent Development
11.9 Histocell
11.9.1 Histocell Company Details
11.9.2 Histocell Business Overview
11.9.3 Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.9.4 Histocell Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.9.5 Histocell Recent Development
11.10 FUJIFILM Diosynth Biotechnologies
11.10.1 FUJIFILM Diosynth Biotechnologies Company Details
11.10.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.10.3 FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.10.4 FUJIFILM Diosynth Biotechnologies Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.10.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.11 Taiwan Bio Therapeutics
11.11.1 Taiwan Bio Therapeutics Company Details
11.11.2 Taiwan Bio Therapeutics Business Overview
11.11.3 Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.11.4 Taiwan Bio Therapeutics Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.11.5 Taiwan Bio Therapeutics Recent Development
11.12 Encell Co., Ltd.
11.12.1 Encell Co., Ltd. Company Details
11.12.2 Encell Co., Ltd. Business Overview
11.12.3 Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.12.4 Encell Co., Ltd. Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.12.5 Encell Co., Ltd. Recent Development
11.13 Mycenax
11.13.1 Mycenax Company Details
11.13.2 Mycenax Business Overview
11.13.3 Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.13.4 Mycenax Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.13.5 Mycenax Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cell Therapy
1.2.3 Cell-derived Products
1.3 Market by Application
1.3.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Large Pharmaceutical Company
1.3.3 Small and Medium-sized Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Perspective (2020-2031)
2.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Growth Trends by Region
2.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Region (2020-2025)
2.2.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Region (2026-2031)
2.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Dynamics
2.3.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industry Trends
2.3.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers
2.3.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges
2.3.4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Revenue
3.1.1 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Revenue (2020-2025)
3.1.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Players (2020-2025)
3.2 Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue
3.4 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Concentration Ratio
3.4.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2024
3.5 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Head office and Area Served
3.6 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Product and Application
3.7 Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Breakdown Data by Type
4.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Type (2020-2025)
4.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Type (2026-2031)
5 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Breakdown Data by Application
5.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Historic Market Size by Application (2020-2025)
5.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
6.2 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
6.4 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
7.2 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
7.4 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
8.2 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
9.2 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
9.4 Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (2020-2031)
10.2 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.1.4 Lonza Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.1.5 Lonza Recent Development
11.2 uBriGene Biosciences International
11.2.1 uBriGene Biosciences International Company Details
11.2.2 uBriGene Biosciences International Business Overview
11.2.3 uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.2.4 uBriGene Biosciences International Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.2.5 uBriGene Biosciences International Recent Development
11.3 Thermo Fisher
11.3.1 Thermo Fisher Company Details
11.3.2 Thermo Fisher Business Overview
11.3.3 Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.3.4 Thermo Fisher Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.3.5 Thermo Fisher Recent Development
11.4 Creative Biolabs
11.4.1 Creative Biolabs Company Details
11.4.2 Creative Biolabs Business Overview
11.4.3 Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.4.4 Creative Biolabs Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.4.5 Creative Biolabs Recent Development
11.5 REPROCELL
11.5.1 REPROCELL Company Details
11.5.2 REPROCELL Business Overview
11.5.3 REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.5.4 REPROCELL Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.5.5 REPROCELL Recent Development
11.6 ATCC
11.6.1 ATCC Company Details
11.6.2 ATCC Business Overview
11.6.3 ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.6.4 ATCC Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.6.5 ATCC Recent Development
11.7 Beijing CytoNiche Biotech
11.7.1 Beijing CytoNiche Biotech Company Details
11.7.2 Beijing CytoNiche Biotech Business Overview
11.7.3 Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.7.4 Beijing CytoNiche Biotech Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.7.5 Beijing CytoNiche Biotech Recent Development
11.8 OmniaBio
11.8.1 OmniaBio Company Details
11.8.2 OmniaBio Business Overview
11.8.3 OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.8.4 OmniaBio Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.8.5 OmniaBio Recent Development
11.9 Histocell
11.9.1 Histocell Company Details
11.9.2 Histocell Business Overview
11.9.3 Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.9.4 Histocell Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.9.5 Histocell Recent Development
11.10 FUJIFILM Diosynth Biotechnologies
11.10.1 FUJIFILM Diosynth Biotechnologies Company Details
11.10.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.10.3 FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.10.4 FUJIFILM Diosynth Biotechnologies Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.10.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.11 Taiwan Bio Therapeutics
11.11.1 Taiwan Bio Therapeutics Company Details
11.11.2 Taiwan Bio Therapeutics Business Overview
11.11.3 Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.11.4 Taiwan Bio Therapeutics Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.11.5 Taiwan Bio Therapeutics Recent Development
11.12 Encell Co., Ltd.
11.12.1 Encell Co., Ltd. Company Details
11.12.2 Encell Co., Ltd. Business Overview
11.12.3 Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.12.4 Encell Co., Ltd. Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.12.5 Encell Co., Ltd. Recent Development
11.13 Mycenax
11.13.1 Mycenax Company Details
11.13.2 Mycenax Business Overview
11.13.3 Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Introduction
11.13.4 Mycenax Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
11.13.5 Mycenax Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cell Therapy
Table 3. Key Players of Cell-derived Products
Table 4. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2020-2025)
Table 8. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2026-2031)
Table 10. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Trends
Table 11. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers
Table 12. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges
Table 13. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints
Table 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Players (2020-2025)
Table 16. Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service as of 2024)
Table 17. Ranking of Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Headquarters and Area Served
Table 20. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Product and Application
Table 21. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Type (2020-2025)
Table 25. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Type (2026-2031)
Table 27. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Application (2020-2025)
Table 29. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Application (2026-2031)
Table 31. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 46. Lonza Company Details
Table 47. Lonza Business Overview
Table 48. Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 49. Lonza Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 50. Lonza Recent Development
Table 51. uBriGene Biosciences International Company Details
Table 52. uBriGene Biosciences International Business Overview
Table 53. uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 54. uBriGene Biosciences International Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 55. uBriGene Biosciences International Recent Development
Table 56. Thermo Fisher Company Details
Table 57. Thermo Fisher Business Overview
Table 58. Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 59. Thermo Fisher Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 60. Thermo Fisher Recent Development
Table 61. Creative Biolabs Company Details
Table 62. Creative Biolabs Business Overview
Table 63. Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 64. Creative Biolabs Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 65. Creative Biolabs Recent Development
Table 66. REPROCELL Company Details
Table 67. REPROCELL Business Overview
Table 68. REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 69. REPROCELL Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 70. REPROCELL Recent Development
Table 71. ATCC Company Details
Table 72. ATCC Business Overview
Table 73. ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 74. ATCC Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 75. ATCC Recent Development
Table 76. Beijing CytoNiche Biotech Company Details
Table 77. Beijing CytoNiche Biotech Business Overview
Table 78. Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 79. Beijing CytoNiche Biotech Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 80. Beijing CytoNiche Biotech Recent Development
Table 81. OmniaBio Company Details
Table 82. OmniaBio Business Overview
Table 83. OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 84. OmniaBio Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 85. OmniaBio Recent Development
Table 86. Histocell Company Details
Table 87. Histocell Business Overview
Table 88. Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 89. Histocell Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 90. Histocell Recent Development
Table 91. FUJIFILM Diosynth Biotechnologies Company Details
Table 92. FUJIFILM Diosynth Biotechnologies Business Overview
Table 93. FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 94. FUJIFILM Diosynth Biotechnologies Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 95. FUJIFILM Diosynth Biotechnologies Recent Development
Table 96. Taiwan Bio Therapeutics Company Details
Table 97. Taiwan Bio Therapeutics Business Overview
Table 98. Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 99. Taiwan Bio Therapeutics Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 100. Taiwan Bio Therapeutics Recent Development
Table 101. Encell Co., Ltd. Company Details
Table 102. Encell Co., Ltd. Business Overview
Table 103. Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 104. Encell Co., Ltd. Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 105. Encell Co., Ltd. Recent Development
Table 106. Mycenax Company Details
Table 107. Mycenax Business Overview
Table 108. Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 109. Mycenax Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 110. Mycenax Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Picture
Figure 2. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Type: 2024 VS 2031
Figure 4. Cell Therapy Features
Figure 5. Cell-derived Products Features
Figure 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Application: 2024 VS 2031
Figure 8. Large Pharmaceutical Company Case Studies
Figure 9. Small and Medium-sized Pharmaceutical Company Case Studies
Figure 10. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Report Years Considered
Figure 11. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region: 2024 VS 2031
Figure 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Players in 2024
Figure 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2024
Figure 17. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 19. United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 23. Germany Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2020-2031)
Figure 31. China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 39. Mexico Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 43. Turkey Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Lonza Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 47. uBriGene Biosciences International Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 48. Thermo Fisher Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 49. Creative Biolabs Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 50. REPROCELL Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 51. ATCC Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 52. Beijing CytoNiche Biotech Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 53. OmniaBio Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 54. Histocell Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 55. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 56. Taiwan Bio Therapeutics Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 57. Encell Co., Ltd. Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 58. Mycenax Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cell Therapy
Table 3. Key Players of Cell-derived Products
Table 4. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2020-2025)
Table 8. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2026-2031)
Table 10. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Trends
Table 11. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers
Table 12. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges
Table 13. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints
Table 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Players (2020-2025)
Table 16. Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service as of 2024)
Table 17. Ranking of Global Top Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Headquarters and Area Served
Table 20. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Product and Application
Table 21. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Type (2020-2025)
Table 25. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Type (2026-2031)
Table 27. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Application (2020-2025)
Table 29. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Application (2026-2031)
Table 31. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country (2026-2031) & (US$ Million)
Table 46. Lonza Company Details
Table 47. Lonza Business Overview
Table 48. Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 49. Lonza Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 50. Lonza Recent Development
Table 51. uBriGene Biosciences International Company Details
Table 52. uBriGene Biosciences International Business Overview
Table 53. uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 54. uBriGene Biosciences International Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 55. uBriGene Biosciences International Recent Development
Table 56. Thermo Fisher Company Details
Table 57. Thermo Fisher Business Overview
Table 58. Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 59. Thermo Fisher Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 60. Thermo Fisher Recent Development
Table 61. Creative Biolabs Company Details
Table 62. Creative Biolabs Business Overview
Table 63. Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 64. Creative Biolabs Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 65. Creative Biolabs Recent Development
Table 66. REPROCELL Company Details
Table 67. REPROCELL Business Overview
Table 68. REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 69. REPROCELL Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 70. REPROCELL Recent Development
Table 71. ATCC Company Details
Table 72. ATCC Business Overview
Table 73. ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 74. ATCC Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 75. ATCC Recent Development
Table 76. Beijing CytoNiche Biotech Company Details
Table 77. Beijing CytoNiche Biotech Business Overview
Table 78. Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 79. Beijing CytoNiche Biotech Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 80. Beijing CytoNiche Biotech Recent Development
Table 81. OmniaBio Company Details
Table 82. OmniaBio Business Overview
Table 83. OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 84. OmniaBio Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 85. OmniaBio Recent Development
Table 86. Histocell Company Details
Table 87. Histocell Business Overview
Table 88. Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 89. Histocell Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 90. Histocell Recent Development
Table 91. FUJIFILM Diosynth Biotechnologies Company Details
Table 92. FUJIFILM Diosynth Biotechnologies Business Overview
Table 93. FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 94. FUJIFILM Diosynth Biotechnologies Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 95. FUJIFILM Diosynth Biotechnologies Recent Development
Table 96. Taiwan Bio Therapeutics Company Details
Table 97. Taiwan Bio Therapeutics Business Overview
Table 98. Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 99. Taiwan Bio Therapeutics Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 100. Taiwan Bio Therapeutics Recent Development
Table 101. Encell Co., Ltd. Company Details
Table 102. Encell Co., Ltd. Business Overview
Table 103. Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 104. Encell Co., Ltd. Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 105. Encell Co., Ltd. Recent Development
Table 106. Mycenax Company Details
Table 107. Mycenax Business Overview
Table 108. Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product
Table 109. Mycenax Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025) & (US$ Million)
Table 110. Mycenax Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Picture
Figure 2. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Type: 2024 VS 2031
Figure 4. Cell Therapy Features
Figure 5. Cell-derived Products Features
Figure 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Application: 2024 VS 2031
Figure 8. Large Pharmaceutical Company Case Studies
Figure 9. Small and Medium-sized Pharmaceutical Company Case Studies
Figure 10. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Report Years Considered
Figure 11. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region: 2024 VS 2031
Figure 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Players in 2024
Figure 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2024
Figure 17. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 19. United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 23. Germany Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Region (2020-2031)
Figure 31. China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 39. Mexico Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Country (2020-2031)
Figure 43. Turkey Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Lonza Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 47. uBriGene Biosciences International Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 48. Thermo Fisher Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 49. Creative Biolabs Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 50. REPROCELL Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 51. ATCC Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 52. Beijing CytoNiche Biotech Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 53. OmniaBio Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 54. Histocell Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 55. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 56. Taiwan Bio Therapeutics Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 57. Encell Co., Ltd. Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 58. Mycenax Revenue Growth Rate in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Ethylene Oxide (EO) Market Research Report 2026
Jan 17, 26
Global Stem Cells Cryopreservation Equipments Market Research Report 2026
Jan 17, 26
Global Selenium-enriched Yeast Market Research Report 2026
Jan 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232